Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
14/10/2026 11:24
BRIEF-Mayne Pharma Says Supreme Court Dismisses Cosette Appeal Oct 14 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
SUPREME COURT DECISION IN COSETTE PROCEEDINGS
SUPREME COURT DISMISSES COSETTE APPEAL AND AWARDS COSTS TO MAYNE PHARMA
COURT UPHOLDS NO MAYNE MATERIAL ADVERSE CHANGE AND NO MISLEADING FY25 EBITDA CONDUCT
COURT OF APPEAL REJECTS ALL COSETTE ARGUMENTS AND AFFIRMS JUSTICE BLACK FINDINGS
COURT OF APPEAL AWARDS MAYNE PHARMA COSTS OF APPEAL, AMOUNT TO BE DETERMINED
COSETTE HAS UNTIL NOV 11, 2026 TO CONSIDER APPEAL TO HIGH COURT
Further company coverage: MYX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)